SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-004528
Filing Date
2024-04-01
Accepted
2024-04-01 16:15:27
Documents
14
Period of Report
2024-04-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xlo-20240401x8k.htm   iXBRL 8-K 52395
2 EX-99.1 xlo-20240401xex99d1.htm EX-99.1 135627
  Complete submission text file 0001558370-24-004528.txt   327303

Data Files

Seq Description Document Type Size
3 EX-101.SCH xlo-20240401.xsd EX-101.SCH 3112
4 EX-101.LAB xlo-20240401_lab.xml EX-101.LAB 16576
5 EX-101.PRE xlo-20240401_pre.xml EX-101.PRE 10706
17 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20240401x8k_htm.xml XML 4995
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

IRS No.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40925 | Film No.: 24809465
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)